Isarna Therapeutics
Germany - MunichBiotechnology
Focus: Isarna Therapeutics is a German biotech focused on synthetic nucleotide therapeutics targeting oncology and ophthalmology indications. The company operates as a clinical-stage biotech with a pipeline of antisense oligonucleotide and related programs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Isarna Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Isarna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TGF-β2 antisense oligonucleotide
Primary Open Angle GlaucomaClinical Trials (1)
NCT02406833Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
Phase 1Help build intelligence for Isarna Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.